| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-737 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.4 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.4 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.06 | 0.4 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |